Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry

Executive Summary

Agency reviewers believed the line between patient input and external intimidation had been crossed; early data from the Sarepta muscular dystrophy drug's flawed development program stoked patient community expectations and made regulatory review difficult.

Advertisement

Related Content

Small Biopharmas Should Be Wary Of Early Results – US FDA Official
Duchenne Development: Six-Minute Walk Losing Favor?
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Eteplirsen Review Timeline: CDER Director Was Involved Early And Often
Sarepta's Eteplirsen Approved After Contentious Internal Debate
FDA Neurology Clinical Team Leader Departure May Be Mountain Disguised As Molehill
FDA To Join The 'Real World' Under PDUFA VI
Sarepta's Eteplirsen Review Delay Emboldens Duchenne Community
Duchenne Group's Presentation Is Milestone For Patient Involvement
Patient Engagement Needs 'Regulatory Guardrails' To Encourage Firms, Advocates Say

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register